FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of neuroendocrinology2005; 17(2); 73-80; doi: 10.1111/j.1365-2826.2005.01277.x

Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.

Abstract: Equine pituitary pars intermedia dysfunction (PPID) is a spontaneously occurring progressive disease affecting aged horses and ponies. The pathogenesis of PPID is poorly understood, but the available evidence supports a loss of dopaminergic inhibition of the melanotropes of the pars intermedia. Horses with PPID have increased plasma concentrations of pars intermedia pro-opiomelanocortin-derived peptides that decrease in response to dopamine or dopamine agonist administration. Dopamine and dopamine metabolite concentrations are decreased in the pars intermedia of affected horses compared to age-matched control horses. Horses with disease that are treated with the dopamine agonist pergolide show improvement in clinical signs and normalisation of diagnostic test results. In the present study, immunohistochemical evaluation of pituitary and hypothalamic tissue demonstrated reduced tyrosine hydroxylase immunoreactivity in affected horses compared to age-matched and young controls, supporting the role of dopaminergic neurodegeneration in PPID. In addition, immunohistochemical evaluation revealed an increase in the oxidative stress marker, 3-nitrotyrosine and in nerve terminal protein, alpha-synuclein that colocalised in the pars intermedia of horses with disease. These findings suggest a role for nitration of overexpressed alpha-synuclein in the pathogenesis of neurodegeneration in PPID.
Get Full Text
Publication Date: 2005-03-31 PubMed ID: 15796757DOI: 10.1111/j.1365-2826.2005.01277.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article explores the connection between certain biological markers and the disease known as equine pituitary pars intermedia dysfunction (PPID) – a prevalent disorder in aged horses. The researchers identify an increase in the specific markers, 3-nitrotyrosine and alpha-synuclein, alongside a decrease in dopaminergic activity as notably linked to the progression of PPID.

Background

The study investigates PPID, a disease in older horses characterized by various symptoms like loss of muscle mass, abnormal hair growth and others. While the exact cause of PPID is not well-understood, it is believed to be associated with a decline in the regulation activity of dopaminergic (associated with the neurotransmitter dopamine) cells of the pars intermedia – a part of the horse’s pituitary gland. This decrease in dopaminergic regulation correlates with augmenting peptide concentrations, resulting in the aforementioned symptoms. Treatment of PPID often includes administration of dopamine or dopamine agonists, which help normalize these peptide concentrations, alleviating some symptoms of the disease.

Method

To better understand the pathogenesis of PPID, the authors executed an immunohistochemical evaluation of pituitary and hypothalamic horse tissue, focusing particularly on the pars intermedia. This evaluation included age-matched and young control horses as well as horses with PPID.

  • They focused on the level of activity of tyrosine hydroxylase, a primary enzyme responsible for dopamine production – reduced activity was observed in horses with PPID.
  • They also looked at the concentrations of 3-nitrotyrosine, an oxidative stress marker, and alpha-synuclein, a nerve terminal protein. Both of these were found to be elevated in PPID-affected horses.

Findings

These findings offer insight into the pathogenesis of PPID. The reduced tyrosine hydroxylase activity confirmed the idea of a decreased dopaminergic activity being involved in PPID. More importantly, the increased presence of 3-nitrotyrosine and alpha-synuclein in the pars intermedia indicates these two factors’ role in the neurodegenerative aspect of PPID.

Implications

These results suggest a possible correlation between increased nitration of alpha-synuclein, triggered by higher levels of 3-nitrotyrosine, and the neurodegenerative aspect of PPID in horses. The study contributes to the scientific understanding of PPID and its underlying mechanisms, paving the way for potential new therapies targeting the observed abnormalities.

Cite This Article

APA
McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. (2005). Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol, 17(2), 73-80. https://doi.org/10.1111/j.1365-2826.2005.01277.x

Publication

Journal of neuroendocrinology
ISSN: 0953-8194
NlmUniqueID: 8913461
Country: United States
Language: English
Volume: 17
Issue: 2
Pages: 73-80

Researcher Affiliations

McFarlane, D
  • Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences, Atlantic Veterinary College, Charlottetown, PE, Canada. dmcfarlane@upei.ca
Dybdal, N
    Donaldson, M T
      Miller, L
        Cribb, A E

          MeSH Terms

          • Animals
          • Blotting, Western
          • Chronic Disease
          • Dopamine / physiology
          • Horse Diseases / metabolism
          • Horse Diseases / pathology
          • Horses
          • Immunohistochemistry
          • Nerve Degeneration / metabolism
          • Nerve Degeneration / pathology
          • Nerve Degeneration / veterinary
          • Nerve Tissue Proteins / metabolism
          • Nitrogen / metabolism
          • Oxidative Stress
          • Pituitary ACTH Hypersecretion / metabolism
          • Pituitary ACTH Hypersecretion / pathology
          • Pituitary ACTH Hypersecretion / veterinary
          • Pituitary Gland / metabolism
          • Pituitary Gland / pathology
          • Synucleins
          • Tyrosine / analogs & derivatives
          • Tyrosine / metabolism
          • Tyrosine 3-Monooxygenase / metabolism
          • alpha-Synuclein

          Citations

          This article has been cited 26 times.
          1. Vaikath N, Sudhakaran I, Abdi I, Gupta V, Majbour N, Ghanem S, Abdesselem H, Vekrellis K, El-Agnaf O. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers. Int J Mol Sci 2022 Nov 23;23(23).
            doi: 10.3390/ijms232314630pubmed: 36498957google scholar: lookup
          2. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses. Vet Sci 2022 Oct 10;9(10).
            doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
          3. Fortin JS, Hetak AA, Duggan KE, Burglass CM, Penticoff HB, Schott HC 2nd. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy. Sci Rep 2021 Aug 6;11(1):16036.
            doi: 10.1038/s41598-021-95396-7pubmed: 34362943google scholar: lookup
          4. Bastian P, Dulski J, Roszmann A, Jacewicz D, Kuban-Jankowska A, Slawek J, Wozniak M, Gorska-Ponikowska M. Regulation of Mitochondrial Dynamics in Parkinson's Disease-Is 2-Methoxyestradiol a Missing Piece?. Antioxidants (Basel) 2021 Feb 6;10(2).
            doi: 10.3390/antiox10020248pubmed: 33562035google scholar: lookup
          5. Tatum RC, McGowan CM, Dean RS, Ireland JL. Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership. PLoS One 2021;16(1):e0244784.
            doi: 10.1371/journal.pone.0244784pubmed: 33395695google scholar: lookup
          6. Horn R, Stewart AJ, Jackson KV, Dryburgh EL, Medina-Torres CE, Bertin FR. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses. J Vet Intern Med 2021 Jan;35(1):560-570.
            doi: 10.1111/jvim.16017pubmed: 33368633google scholar: lookup
          7. Fortin JS, Benskey MJ, Lookingland KJ, Patterson JS, Howey EB, Goudreau JL, Schott HC 2nd. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. BMC Vet Res 2020 Sep 25;16(1):356.
            doi: 10.1186/s12917-020-02565-3pubmed: 32977825google scholar: lookup
          8. Żak A, Siwińska N, Chełmecka E, Bażanów B, Romuk E, Adams A, Niedźwiedź A, Stygar D. Effects of Advanced Age, Pituitary Pars Intermedia Dysfunction and Insulin Dysregulation on Serum Antioxidant Markers in Horses. Antioxidants (Basel) 2020 May 21;9(5).
            doi: 10.3390/antiox9050444pubmed: 32455574google scholar: lookup
          9. Held F, Ekstrand C, Cvijovic M, Gabrielsson J, Jirstrand M. Modelling of oscillatory cortisol response in horses using a Bayesian population approach for evaluation of dexamethasone suppression test protocols. J Pharmacokinet Pharmacodyn 2019 Feb;46(1):75-87.
            doi: 10.1007/s10928-018-09617-0pubmed: 30673914google scholar: lookup
          10. Spelta CW. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management. Vet Med (Auckl) 2015;6:293-300.
            doi: 10.2147/VMRR.S74191pubmed: 30101114google scholar: lookup
          11. Li T, Feng Y, Yang R, Wu L, Li R, Huang L, Yang Q, Chen J. Salidroside Promotes the Pathological α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells. Front Pharmacol 2018;9:377.
            doi: 10.3389/fphar.2018.00377pubmed: 29725300google scholar: lookup
          12. Carmalt JL, Mortazavi S, McOnie RC, Allen AL, Unniappan S. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction. PLoS One 2018;13(1):e0190796.
            doi: 10.1371/journal.pone.0190796pubmed: 29309431google scholar: lookup
          13. Carmalt JL, Waldner CL, Allen AL. Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence. Can J Vet Res 2017 Oct;81(4):261-269.
            pubmed: 29081583
          14. Hatazoe T, Kawaguchi H, Hobo S, Misumi K. Pituitary pars intermedia dysfunction (equine Cushing's disease) in a Thoroughbred stallion: a single report. J Equine Sci 2015;26(4):125-8.
            doi: 10.1294/jes.26.125pubmed: 26858577google scholar: lookup
          15. Sampaio-Marques B, Ludovico P. Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies. Biomolecules 2015 May 4;5(2):735-57.
            doi: 10.3390/biom5020735pubmed: 25946078google scholar: lookup
          16. Johnson PJ, Wiedmeyer CE, LaCarrubba A, Ganjam VK, Messer NT 4th. Diabetes, insulin resistance, and metabolic syndrome in horses. J Diabetes Sci Technol 2012 May 1;6(3):534-40.
            doi: 10.1177/193229681200600307pubmed: 22768883google scholar: lookup
          17. Johnson PJ, Wiedmeyer CE, Messer NT, Ganjam VK. Medical implications of obesity in horses--lessons for human obesity. J Diabetes Sci Technol 2009 Jan;3(1):163-74.
            doi: 10.1177/193229680900300119pubmed: 20046661google scholar: lookup
          18. Haritou SJ, Zylstra R, Ralli C, Turner S, Tortonese DJ. Seasonal changes in circadian peripheral plasma concentrations of melatonin, serotonin, dopamine and cortisol in aged horses with Cushing's disease under natural photoperiod. J Neuroendocrinol 2008 Aug;20(8):988-96.
            doi: 10.1111/j.1365-2826.2008.01751.xpubmed: 18540997google scholar: lookup
          19. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008 Feb;118(2):777-88.
            doi: 10.1172/JCI32806pubmed: 18172548google scholar: lookup
          20. Massardi E, Gaudenzi G, Carra S, Oldani M, Rybinska I, Persani L, Vitale G. Cushing's Disease in the Animal Kingdom: Translational Insights for Human Medicine. Int J Mol Sci 2025 Sep 4;26(17).
            doi: 10.3390/ijms26178626pubmed: 40943544google scholar: lookup
          21. Menzies-Gow NJ. Equine Pituitary Pars Intermedia Dysfunction. Vet Sci 2025 Aug 20;12(8).
            doi: 10.3390/vetsci12080780pubmed: 40872730google scholar: lookup
          22. Vaughn SA, Lemons MB, Hart KA. The Effect of Season and Breed on Hypothalamic-Pituitary-Adrenal Axis Hormones, Metabolic Hormones, and Oxidative Markers in Ponies and Horses. J Vet Intern Med 2025 Mar-Apr;39(2):e70047.
            doi: 10.1111/jvim.70047pubmed: 40048369google scholar: lookup
          23. Wang W, Gibson J, Horsman S, Mikkelsen D, Bertin FR. Characterization and comparison of fecal microbiota in horses with pituitary pars intermedia dysfunction and age-matched controls. J Vet Intern Med 2025 Jan-Feb;39(1):e17288.
            doi: 10.1111/jvim.17288pubmed: 39853825google scholar: lookup
          24. Neufang L, Ramos J, Eda S, Flatland B, Giori L. Initial development of a rapid, portable, stall-side ELISA for the measurement of equine adrenocorticotropic hormone. J Vet Diagn Invest 2025 Jan;37(1):208-211.
            doi: 10.1177/10406387241285453pubmed: 39320416google scholar: lookup
          25. Takahashi N, Chambers JK, Ota K, Toda K, Yoshimoto Y, Miyajima U, Uchida K. Pituitary pars intermedia dysfunction with pituitary gland melanotroph adenoma in a Grevy's zebra (Equus grevyi). J Vet Med Sci 2024 Jan 10;86(1):71-76.
            doi: 10.1292/jvms.23-0177pubmed: 37981318google scholar: lookup
          26. Nechushtai L, Frenkel D, Pinkas-Kramarski R. Autophagy in Parkinson's Disease. Biomolecules 2023 Sep 22;13(10).
            doi: 10.3390/biom13101435pubmed: 37892117google scholar: lookup
          Subscribe to our newsletter
          Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.